August 19th 2021
Lyndsay Willmott, MD, discusses the expanding role for genomic testing in ovarian cancer.
August 9th 2021
Lyndsay Willmott, MD, discusses the importance of genetic testing in ovarian cancer.
July 29th 2021
Lyndsay Willmott, MD, discusses selecting among available PARP inhibitors for the treatment of patients with ovarian cancer based on genetic testing results.
April 16th 2018
Lyndsay J. Willmott, MD, gynecologic oncologist, Arizona Oncology, discusses the mechanisms of resistance to PARP inhibitors that have been identified in ovarian cancer.